Cargando…

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria

OBJECTIVE: We investigated whether the antiproteinuric effect of the direct renin inhibitor aliskiren is comparable to that of irbesartan and the effect of the combination. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, crossover trial. After a 1-month washout period, 26 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Frederik, Rossing, Peter, Reinhard, Henrik, Juhl, Tina, Stehouwer, Coen D.A., Schalkwijk, Casper, Danser, A.H. Jan, Boomsma, Frans, Frandsen, Erik, Parving, Hans-Henrik
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752919/ https://www.ncbi.nlm.nih.gov/pubmed/19587362 http://dx.doi.org/10.2337/dc09-0168

Ejemplares similares

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort
por: Ferreira, Isabel, et al.
Publicado: (2017)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
por: Nin, Johanna W., et al.
Publicado: (2011)

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
por: Piazza, M., et al.
Publicado: (2020)

Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-Year Follow-Up Study
por: Nin, Johanna W.M., et al.
Publicado: (2010)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria
por: Rathcke, Camilla Noelle, et al.
Publicado: (2009)

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies
por: Peeters, Stijn A., et al.
Publicado: (2017)

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria
por: Winther, Signe Abitz, et al.
Publicado: (2021)

N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk
por: Idzerda, Nienke M. A., et al.
Publicado: (2018)

Comment on: Selvin et al. sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. Diabetes 2013;62:2116–2121
por: Schalkwijk, Casper G., et al.
Publicado: (2013)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
por: Sureshkumar, Kalathil K
Publicado: (2008)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

Aliskiren suppresses the renin–angiotensin–aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Aliskiren and valsartan combination therapy for the management of hypertension
por: Epstein, Benjamin J
Publicado: (2010)

Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances
por: van Greevenbroek, Marleen M. J., et al.
Publicado: (2016)

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
por: McMurray, John J.V., et al.
Publicado: (2012)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
por: Bramlage, Peter
Publicado: (2009)

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
por: Peeters, S. A., et al.
Publicado: (2017)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Irbesartan in experimental diabetic nephropathy
por: Mahajan, Rajiv, et al.
Publicado: (2010)

Aliskiren in hypertension: evidence for its potential therapeutic value
por: Peter, Doris
Publicado: (2005)

Aliskiren: An orally active renin inhibitor
por: Wal, Pranay, et al.
Publicado: (2011)

Aliskiren and the dual complement inhibition concept
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

Direct Renin Inhibition: Focus on Aliskiren
por: Pool, James L.
Publicado: (2007)

Long-term use and tolerability of irbesartan for control of hypertension
por: Forni, Valentina, et al.
Publicado: (2011)

Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
por: Nin, J. W. M., et al.
Publicado: (2012)

Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial
por: Top, Wiebe M. C., et al.
Publicado: (2021)

Can Aliskiren be Considered as a New Novel Drug for Hypertension?
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2011)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
por: Andersen, Sten, et al.
Publicado: (2010)

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
por: Lund, Søren Søgaard, et al.
Publicado: (2008)

Role of aliskiren in blood pressure control and renoprotection
por: Trimarchi, Hernán
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jbg9frp3gb8im36k0bs97sr412